These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35067241)

  • 1. Evaluation of fidaxomicin use in community hospitals after a clinical guideline change at a large health system and opportunities for stewardship.
    Khadem TM; Nguyen MH; Bariola JR
    Infect Control Hosp Epidemiol; 2023 Feb; 44(2):312-314. PubMed ID: 35067241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Fidaxomicin Hospital Discharges of Adult Patients With Clostridioides difficile Infections Post-2021 Guidelines: Are Economic Barriers Finally Coming Down?
    Fang N; Ha D; Dong K; Leung T; Lee S; Holubar M; Meng L
    Clin Infect Dis; 2022 Aug; 75(3):519-521. PubMed ID: 34971358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Clostridioides difficile Infection: Diagnosis, Treatment, and Future Perspectives.
    Cymbal M; Chatterjee A; Baggott B; Auron M
    Am J Med; 2024 Jul; 137(7):571-576. PubMed ID: 38508330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fidaxomicin for the treatment of
    Skinner AM; Scardina T; Kociolek LK
    Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained reductions in unnecessary antimicrobial administration and hospital
    Gaffin N; Spellberg B
    Infect Control Hosp Epidemiol; 2023 Mar; 44(3):491-493. PubMed ID: 34915961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outpatient
    Morrison AR; Kenney RM; Davis SL
    Infect Control Hosp Epidemiol; 2020 Aug; 41(8):969-971. PubMed ID: 32484121
    [No Abstract]   [Full Text] [Related]  

  • 7. In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile.
    Marchandin H; Anjou C; Poulen G; Freeman J; Wilcox M; Jean-Pierre H; Barbut F
    J Antimicrob Chemother; 2023 Aug; 78(8):1992-1999. PubMed ID: 37352110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clostridioides difficile Colitis.
    Pumiglia L; Wilson L; Rashidi L
    Surg Clin North Am; 2024 Jun; 104(3):545-556. PubMed ID: 38677819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial stewardship program achieved marked decrease in Clostridium difficile infections in a Veterans Hospital.
    Morgan F; Belal M; Lisa B; Ford F; LeMaitre B; Psevdos G
    Am J Infect Control; 2020 Sep; 48(9):1119-1121. PubMed ID: 32035688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a prospective audit with intervention and feedback on Clostridioides difficile infection management.
    Benoist H; de La Blanchardière A; Flatres A; Isnard C; Thibon P; Saint-Lorant G
    Int J Clin Pharm; 2020 Jun; 42(3):923-930. PubMed ID: 32410207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile.
    Cao X; Boyaci H; Chen J; Bao Y; Landick R; Campbell EA
    Nature; 2022 Apr; 604(7906):541-545. PubMed ID: 35388215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of diagnostic and antimicrobial stewardship practices to improve
    Sullivan KV; Gallagher JC; Leekha S; Morgan DJ; Morita K; Rock C; Claeys KC
    Infect Control Hosp Epidemiol; 2022 Jul; 43(7):930-934. PubMed ID: 34376271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection Recurrences.
    Skinner AM; Tan X; Sirbu BD; Danziger LH; Gerding DN; Johnson S
    Clin Infect Dis; 2021 Sep; 73(6):1107-1109. PubMed ID: 33714998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.
    Turner NA; Warren BG; Gergen-Teague MF; Addison RM; Addison B; Rutala WA; Weber DJ; Sexton DJ; Anderson DJ
    Clin Infect Dis; 2022 Mar; 74(4):648-656. PubMed ID: 34017999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and Treatment of Clostridioides (Clostridium) difficile Infection in Adults in 2020.
    Rao K; Malani PN
    JAMA; 2020 Apr; 323(14):1403-1404. PubMed ID: 32150234
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clostridioides difficile: updated recommendations].
    Barbut F; Eckert C; Lalande V; Le Neindre K; Couturier J
    Rev Prat; 2022 Sep; 72(7):703-709. PubMed ID: 36511953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?
    Krutova M; Wilcox M; Kuijper E
    Int J Infect Dis; 2022 Nov; 124():118-123. PubMed ID: 36155825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clostridioides difficile Infection in Children: The Role of Infection Prevention and Antimicrobial Stewardship.
    Savage TJ; Sandora TJ
    J Pediatric Infect Dis Soc; 2021 Nov; 10(Supplement_3):S64-S68. PubMed ID: 34791402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clostridioides difficile infection: various therapeutic approaches].
    Meuwly M; Chuard C
    Rev Med Suisse; 2022 Oct; 18(799):1896-1899. PubMed ID: 36226451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.